GlassScriptPhysician profile
Robert M Tognacci
NPI 1669404711
$5,817.28
in general payments reported to CMS, 2019-2025
41 companies · $817 in 2025
The $817 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $723 · 2021: $361 · 2022: $1,154 · 2023: $933 · 2024: $1,169 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,918.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,191.14 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,069.75 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Novo Nordisk INC | $466.43 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.21 | 2019-2025 | Jardiance |
| Pfizer INC. | $315.59 | 2020-2025 | |
| Allergan, INC. | $297.55 | 2019-2020 | |
| Glaxosmithkline, LLC. | $192.16 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boston Scientific Corporation | $147.81 | 2019-2025 | General - Pain Management |
| Abbott Laboratories | $130.37 | 2019-2025 | Proclaim, Freestyle Libre 3 |
| Lilly USA, LLC | $121.24 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $115.73 | 2022-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $109.00 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Novartis Pharmaceuticals Corporation | $104.63 | 2019-2025 | |
| Sanofi Pasteur INC. | $92.95 | 2020-2025 | |
| Nevro Corp. | $83.57 | 2021-2023 | Senza |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tognacci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.